Teva Pharmaceutical Industries Ltd. climbed in New York, pushing the premium over Israeli stock to a six-week high, on speculation the drugmaker is settling lawsuits alleging a treatment led patients to develop hepatitis C. Teva Premium Swells on $250 Million Settlement: Israel Overnight 3 businessweek.com
